article thumbnail

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

BioPharma Dive

The company’s share price is lower by more than 80% this year amid concerns about Elevidys’ future and the chance new FDA leadership might restrict its use. The company also has $1 billion in senior notes coming due in 2027. By Jonathan Gardner • Sept. as Scientific Advisor From Receptor.AI By Jonathan Gardner • Sept.

article thumbnail

STAT+: In Ireland, a global hub for the pharma industry, Trump tariffs are a source of deep worry

STAT

The hulking factories are tucked away off the roads around the village of Ringaskiddy — operated by the likes of Pfizer, Johnson & Johnson, and BioMarin, whose plant featured signs last week touting a new facility “coming Q1 2027.” In his view, the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

EHDS regulation will depend on strong patient confidence

Pharmaceutical Technology

The European Commission (EC) faces a March 2027 deadline to adopt several key implementing acts, which will lay out detailed rules for putting the regulation into practice. The regulation came into force in March 2025; however, it has not yet come into application, with this set to happen in March 2029.

article thumbnail

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen

pharmaphorum

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.

article thumbnail

Bristol Myers, bracing for key patent losses, deepens cost-cutting plan

BioPharma Dive

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference call.

article thumbnail

Amgen opens its most advanced manufacturing facility to date

European Pharmaceutical Review

The facility has been designed to meet the highest environmental sustainability standards, to help Amgen’s reach its target of carbon neutrality in all operations by 2027, the company noted. The post Amgen opens its most advanced manufacturing facility to date appeared first on European Pharmaceutical Review.